mAbxience
↗Madrid, Spain
mAbxience is a global, vertically integrated biotechnology company specializing in the development, manufacture, and commercialization of biosimilar medicines and innovative biopharmaceuticals. Founded in 2010, the company operates as a major player in the B2B biopharmaceutical space, providing both proprietary products and high-end Contract Development and Manufacturing Organization (CDMO) services.
In 2022, Fresenius Kabi acquired a 55% majority stake in mAbxience to accelerate its biopharmaceuticals growth strategy. The company maintains state-of-the-art manufacturing facilities in Spain and Argentina, utilizing single-use technology to produce monoclonal antibodies and vaccines for over 100 markets worldwide.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$600M-$700M (Biopharma Segment)
Founded:2009
Ownership:subsidiary
Status:operating
FUNDING
Stage:Acquired
Total Raised:$551M (Acquisition Value)
Investors:Fresenius Kabi, Insud Pharma
STOCK
Exchange:ETR (Parent: FRE)
Ticker:FRE
Market Cap:$15B-$20B (Parent Fresenius SE)
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:mAb, Biosimilars, Vaccines
Active Trials:5
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 3
FDA Approvals:3
EMA Approvals:4
CORPORATE STRUCTURE
Parent Company:Fresenius Kabi
Acquired By:Fresenius Kabi (2022-03-01)
Subsidiaries:mAbxience SAU (Argentina), Genhelix (Spain)
Key Partnerships:Abbott (Emerging markets distribution), Teva (Biosimilar commercialization), Amneal Pharmaceuticals (US market license), Intas Pharmaceuticals (Etanercept licensing), HP Inc. (AI in biomanufacturing)
COMPETITION
Position:Leader
Competitors:Sandoz, Samsung Bioepis, Celltrion, Amgen, Biogen
LEADERSHIP
Key Executives:
Emmanuelle Lepine - CEO
Francisco Olivera - Global Operations Director
Scientific Founders:Dr. Hugo Sigman, Dr. Silvia Gold
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with mAbxience. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.